BNP Paribas Financial Markets Sells 1,319 Shares of Cassava Sciences, Inc. (NASDAQ:SAVA)

BNP Paribas Financial Markets lessened its position in Cassava Sciences, Inc. (NASDAQ:SAVAFree Report) by 6.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 19,099 shares of the company’s stock after selling 1,319 shares during the period. BNP Paribas Financial Markets’ holdings in Cassava Sciences were worth $430,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of SAVA. Montag A & Associates Inc. increased its stake in Cassava Sciences by 50.0% in the third quarter. Montag A & Associates Inc. now owns 1,500 shares of the company’s stock valued at $25,000 after purchasing an additional 500 shares in the last quarter. Northwest Financial Advisors bought a new stake in Cassava Sciences in the fourth quarter valued at approximately $25,000. Benjamin F. Edwards & Company Inc. increased its position in shares of Cassava Sciences by 653.6% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 1,153 shares of the company’s stock worth $26,000 after acquiring an additional 1,000 shares in the last quarter. Headlands Technologies LLC increased its position in shares of Cassava Sciences by 24,044.4% during the third quarter. Headlands Technologies LLC now owns 2,173 shares of the company’s stock worth $36,000 after acquiring an additional 2,164 shares in the last quarter. Finally, NBC Securities Inc. bought a new stake in shares of Cassava Sciences during the third quarter worth $66,000. Institutional investors own 38.05% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright increased their price objective on shares of Cassava Sciences from $124.00 to $131.00 and gave the stock a “buy” rating in a research report on Friday, May 17th.

View Our Latest Analysis on SAVA

Cassava Sciences Stock Down 0.1 %

Shares of SAVA stock opened at $22.00 on Tuesday. The firm has a fifty day moving average of $21.68 and a 200-day moving average of $21.67. Cassava Sciences, Inc. has a 12-month low of $12.32 and a 12-month high of $32.10. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -10.14 and a beta of -0.49.

Cassava Sciences (NASDAQ:SAVAGet Free Report) last announced its earnings results on Friday, May 10th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.90). On average, equities analysts expect that Cassava Sciences, Inc. will post -1.86 EPS for the current year.

Cassava Sciences Profile

(Free Report)

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.

Read More

Want to see what other hedge funds are holding SAVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cassava Sciences, Inc. (NASDAQ:SAVAFree Report).

Institutional Ownership by Quarter for Cassava Sciences (NASDAQ:SAVA)

Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cassava Sciences and related companies with MarketBeat.com's FREE daily email newsletter.